<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281007</url>
  </required_header>
  <id_info>
    <org_study_id>F125EMS1010</org_study_id>
    <nct_id>NCT01281007</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by
      herpes simplex virus (HSV). There are effective oral prescription antiviral medicines
      available to reduce the discomfort of symptoms, such as famciclovir and aciclovir.

      This is a phase III, multicenter, randomized, parallel-group study to compare the efficacy
      and safety of treatment with famciclovir (125 mg) versus aciclovir (200 mg) in patients with
      active recurrent genital herpes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN

        -  Open-label, prospective, parallel group, intent to treat trial

        -  Experiment duration: 5 days

        -  2 visits (days 1, and 5)

        -  Reduction of symptoms

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation</measure>
    <time_frame>Day 5</time_frame>
    <description>Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Will be Evaluated by the Adverse Events Occurence</measure>
    <time_frame>Day 5</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>GENITAL HERPES</condition>
  <arm_group>
    <arm_group_label>Famciclovir 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet every 12 hours for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aciclovir 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet every 4 hours (excluding nocturnal dose) for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famciclovir</intervention_name>
    <description>Famciclovir 125 mg every 12 hours for 5 days</description>
    <arm_group_label>Famciclovir 125 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aciclovir</intervention_name>
    <description>Aciclovir 200 mg every 4 hours fo 5 days</description>
    <arm_group_label>Aciclovir 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with clinical diagnosis of recurrent genital herpes;

          3. Score symptoms higher than 4;

          4. Negative pregnant urine test.

        Exclusion criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation

          3. Any pathology or past medical condition that can interfere with this protocol.

          4. Non-steroidal anti-inflammatory drug , hormonal anti-inflammatory or immunosuppressive
             drugs (in the last 30 days and during the study);

          5. Patients with immunodeficiency and/or immunosuppressive disease;

          6. Hypersensitivity to components of the formula;

          7. Other conditions deemed reasonable by the medical investigator as to the
             disqualification of the individual from study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Amazonas, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Medicina Reprodutiva Dr Carlos Isaia Filho Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPVita</name>
      <address>
        <city>Braganca Paulista</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caep Centro Avancado de Estudos E Pesquisas Ltda</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMICAMP - Centro de Pesquisas em Saúde Reprodutiva de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CECIP - Centro de Estudos Clínicos do Interior Paulista</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14048900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Sirio Libanes de Ensino e Pesquisa</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01308-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afip - Associacao Fundo de Incentivo A Psicofarmacologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2015</results_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Simplex Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Famciclovir</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Famciclovir 125 mg</title>
          <description>1 tablet every 12 hours for 5 days
Famciclovir: Famciclovir 125 mg every 12 hours for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Aciclovir 200 mg</title>
          <description>1 tablet every 4 hours (excluding nocturnal dose) for 5 days
Aciclovir: Aciclovir 200 mg every 4 hours fo 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Famciclovir 125 mg</title>
          <description>1 tablet every 12 hours for 5 days
Famciclovir: Famciclovir 125 mg every 12 hours for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Aciclovir 200 mg</title>
          <description>1 tablet every 4 hours (excluding nocturnal dose) for 5 days
Aciclovir: Aciclovir 200 mg every 4 hours fo 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation</title>
        <description>Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Famciclovir 125 mg</title>
            <description>1 tablet every 12 hours for 5 days
Famciclovir: Famciclovir 125 mg every 12 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Aciclovir 200 mg</title>
            <description>1 tablet every 4 hours (excluding nocturnal dose) for 5 days
Aciclovir: Aciclovir 200 mg every 4 hours fo 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation</title>
          <description>Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Will be Evaluated by the Adverse Events Occurence</title>
        <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
        <time_frame>Day 5</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Famciclovir 125 mg</title>
          <description>1 tablet every 12 hours for 5 days
Famciclovir: Famciclovir 125 mg every 12 hours for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Aciclovir 200 mg</title>
          <description>1 tablet every 4 hours (excluding nocturnal dose) for 5 days
Aciclovir: Aciclovir 200 mg every 4 hours fo 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager of Clinical Trials</name_or_title>
      <organization>EMS</organization>
      <phone>+5501938877776</phone>
      <email>pesquisa.clinica@ems.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

